(OFIX) Orthofix Medical - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 435m USD | Total Return: -15% in 12m
Avg Turnover: 3.60M
Qual. Beats: 2
Rev. Trend: 84.7%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -2.1 is critical
Altman Z'' -0.41 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Orthofix Medical Inc. (OFIX) is a medical technology company specializing in spinal and orthopedic solutions. The company operates through two primary segments: Global Spine and Global Limb Reconstruction. Its product portfolio includes bone growth stimulation devices, spinal implants, bone graft substitutes, and specialized hardware for limb lengthening and deformity correction. The medical device sector typically requires high research and development investment to navigate complex regulatory approval processes and maintain competitive technological advantages.
The company also develops digital surgical navigation technologies, such as the 7D FLASH Navigation System, which utilizes machine-vision and optical innovations for spinal and cranial procedures. Orthofix utilizes a hybrid distribution model, selling its products through a network of distributors and direct sales representatives to hospitals and ambulatory surgery centers. In the healthcare equipment industry, revenue is often driven by the volume of elective procedures and long-term relationships with specialized surgeons. For a deeper analysis of these market dynamics, you may find additional insights on ValueRay.
Founded in 1980 and headquartered in Lewisville, Texas, Orthofix maintains a global presence with operations in North America, Europe, and South America. The company underwent a corporate name change from Orthofix International N.V. to Orthofix Medical Inc. in 2018 to reflect its evolving focus within the healthcare technology landscape.
- Global Spine segment revenue growth relies on bone growth stimulator market share
- 7D FLASH Navigation System adoption accelerates high-margin surgical technology sales
- Global Limb Reconstruction segment performance hinges on complex fracture and deformity correction demand
- Integration of SeaSpine merger assets impacts operational efficiency and profit margins
- Regulatory approvals for new spinal fixation and bone graft products drive valuation
| Net Income: -60.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 0.17 > 1.0 |
| NWC/Revenue: 36.41% < 20% (prev 30.60%; Δ 5.81% < -1%) |
| CFO/TA 0.04 > 3% & CFO 34.9m > Net Income -60.0m |
| Net Debt (155.0m) to EBITDA (96.0m): 1.62 < 3 |
| Current Ratio: 2.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.5m) vs 12m ago 3.19% < -2% |
| Gross Margin: 69.02% > 18% (prev 0.67%; Δ 6.83k% > 0.5%) |
| Asset Turnover: 96.55% > 50% (prev 97.74%; Δ -1.19% > 0%) |
| Interest Coverage Ratio: -2.11 > 6 (EBITDA TTM 96.0m / Interest Expense TTM 18.6m) |
| A: 0.34 (Total Current Assets 461.5m - Total Current Liabilities 161.0m) / Total Assets 886.6m |
| B: -0.44 (Retained Earnings -389.2m / Total Assets 886.6m) |
| C: -0.05 (EBIT TTM -39.4m / Avg Total Assets 854.9m) |
| D: -0.85 (Book Value of Equity -385.1m / Total Liabilities 451.4m) |
| Altman-Z'' = -0.41 = B |
| DSRI: 1.02 (Receivables 137.8m/131.9m, Revenue 825.4m/804.5m) |
| GMI: 0.97 (GM 69.02% / 67.15%) |
| AQI: 0.97 (AQ_t 0.34 / AQ_t-1 0.35) |
| SGI: 1.03 (Revenue 825.4m / 804.5m) |
| TATA: -0.11 (NI -60.0m - CFO 34.9m) / TA 886.6m) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 9.77 with a total of 981,249 shares traded.
Over the past week, the price has changed by -19.52%,
over one month by -20.70%,
over three months by -25.82% and
over the past year by -14.97%.
Orthofix Medical has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy OFIX.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15 | 53.5% |
P/E Forward = 76.9231
P/S = 0.5265
P/B = 0.9976
P/EG = 7.6714
Revenue TTM = 825.4m USD
EBIT TTM = -39.4m USD
EBITDA TTM = 96.0m USD
Long Term Debt = 221.3m USD (from longTermDebt, last quarter)
Short Term Debt = 115k USD (from shortTermDebt, last quarter)
Debt = 275.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 40.9m
Net Debt = 155.0m USD (calculated: Debt 275.3m - CCE 120.3m)
Enterprise Value = 589.6m USD (434.5m + Debt 275.3m - CCE 120.3m)
Interest Coverage Ratio = -2.11 (Ebit TTM -39.4m / Interest Expense TTM 18.6m)
EV/FCF = -162.5x (Enterprise Value 589.6m / FCF TTM -3.63m)
FCF Yield = -0.62% (FCF TTM -3.63m / Enterprise Value 589.6m)
FCF Margin = -0.44% (FCF TTM -3.63m / Revenue TTM 825.4m)
Net Margin = -7.27% (Net Income TTM -60.0m / Revenue TTM 825.4m)
Gross Margin = 69.02% ((Revenue TTM 825.4m - Cost of Revenue TTM 255.7m) / Revenue TTM)
Gross Margin QoQ = 70.94% (prev 64.59%)
Tobins Q-Ratio = 0.66 (Enterprise Value 589.6m / Total Assets 886.6m)
Interest Expense / Debt = 6.77% (Interest Expense 18.6m / Debt 275.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -31.1m (EBIT -39.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.87 (Total Current Assets 461.5m / Total Current Liabilities 161.0m)
Debt / Equity = 0.63 (Debt 275.3m / totalStockholderEquity, last quarter 435.2m)
Debt / EBITDA = 1.62 (Net Debt 155.0m / EBITDA 96.0m)
Debt / FCF = -42.72 (negative FCF - burning cash) (Net Debt 155.0m / FCF TTM -3.63m)
Total Stockholder Equity = 446.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.02% (Net Income -60.0m / Total Assets 886.6m)
RoE = -7.18% (Net Income TTM -60.0m / Total Stockholder Equity 835.8m)
RoCE = -3.73% (EBIT -39.4m / Capital Employed (Equity 835.8m + L.T.Debt 221.3m))
RoIC = -4.56% (negative operating profit) (NOPAT -31.1m / Invested Capital 681.6m)
WACC = 7.09% (E(434.5m)/V(709.8m) * Re(8.19%) + D(275.3m)/V(709.8m) * Rd(6.77%) * (1-Tc(0.21)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 3.75%
[DCF] Fair Price = unknown (Cash Flow -3.63m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.89 | # QB: 2
Revenue Correlation: 84.68 | Revenue CAGR: 9.51% | SUE: 0.71 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.03 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.05 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=0.19 | Chg30d=N/A | Revisions=+20% | GrowthEPS=-61.0% | GrowthRev=+2.6%
EPS next Year (2027-12-31): EPS=0.71 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+273.7% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: +20%